Leerink Partnrs Comments on Allakos FY2029 Earnings

Allakos Inc. (NASDAQ:ALLK) – Equities researchers at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Allakos in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.20) for the year. The consensus estimate for Allakos’ current full-year earnings is ($1.16) per share.

Allakos (NASDAQ:ALLK) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01.

Several other brokerages have also issued reports on ALLK. Piper Sandler lowered shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Citizens Jmp cut shares of Allakos from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 27th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Allakos presently has a consensus rating of “Hold” and a consensus target price of $2.00.

Allakos Trading Down 3.2 %

Shares of NASDAQ ALLK opened at $0.27 on Thursday. The company has a market cap of $24.12 million, a price-to-earnings ratio of -0.13 and a beta of 0.78. Allakos has a 12 month low of $0.23 and a 12 month high of $1.69. The stock has a 50-day moving average price of $0.94 and a two-hundred day moving average price of $0.87.

Institutional Trading of Allakos

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in Allakos during the 2nd quarter worth approximately $55,000. RBF Capital LLC raised its stake in shares of Allakos by 45.9% during the third quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock valued at $333,000 after acquiring an additional 160,529 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Allakos by 11.9% during the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after purchasing an additional 84,750 shares during the period. Geode Capital Management LLC grew its stake in shares of Allakos by 8.9% in the third quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock worth $646,000 after purchasing an additional 80,763 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Allakos in the third quarter valued at $1,143,000. 84.64% of the stock is currently owned by institutional investors.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.